PATENT CLAIM ANALYSIS

Application Number: 16156983
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "338000"]

Abstract:
The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material.

Claim (Index 14):
An oral pharmaceutical composition, comprising:\n (i) a first component, wherein the first component comprises an active pharmaceutical ingredient or a pharmaceutically acceptable salt or hydrate thereof; and (ii) a second component, wherein the second component comprises:\n (a) a pharmaceutically acceptable surface-modified acidic auxiliary material, wherein the surface of the pharmaceutically acceptable surface-modified acidic auxiliary material comprises a neutral salt layer formed by reacting: 1) a powdered form of an acidic medicinal auxiliary material; and 2) an aqueous solution comprising a pharmaceutically acceptable alkaline substance for surface modification, \n wherein the acidic medicinal auxiliary material is selected from the group consisting of tartaric acid, fumaric acid, succinic acid, citric acid, malic acid, glutamic acid, aspartic acid, a hydrate thereof, and an acidic salt thereof, and \n wherein the pharmaceutically acceptable alkaline substance for modification is selected from the group consisting of aqueous ammonia, meglumine, trihydroxymethylaminomethane, sodium carbonate, potassium carbonate, sodium acetate, potassium acetate, sodium stearate, potassium stearate, lysine, arginine and histidine, and a hydrate thereof; or \n (b) a pharmaceutically acceptable surface-modified alkaline auxiliary material, wherein the surface of the pharmaceutically acceptable surface-modified alkaline auxiliary material comprises a neutral salt layer formed by reacting: 1) a powdered form of an alkaline medicinal auxiliary material; and 2) an aqueous solution comprising a pharmaceutically acceptable acidic substance for modification, \n wherein the alkaline medicinal auxiliary material is selected from the group consisting of lysine, arginine, histidine, and a hydrate thereof, and \n wherein the pharmaceutically acceptable acidic substance for modification is selected from the group consisting of tartaric acid, fumaric acid, succinic acid, citric acid, malic acid, glutamic acid, aspartic acid, a hydrate thereof, and an acidic salt.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 97.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15636353', '15303176', '15308014', '14373163', '14779911']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7740567620217657
- 35 USC 102 Novelty (BERT): 0.5673997371807865
- Combined Prediction Score: 0.7533910595376678
- Mean Citation Score: 326.399218
- Max Citation Score: 490.60538
- Similarity Product: 350.10031716497065

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test